Paraneoplastic acute exudative polymorphous vitelliform maculopathy improved with intravitreal methotrexate.

Abstract

PURPOSE:

To describe a case of acute exudative polymorphous vitelliform maculopathy (AEPVM) treated with intravitreal methotrexate.

OBSERVATIONS:

A 58-year-old man with a history of metastatic melanoma developed paraneoplastic acute exudative polymorphous vitelliform maculopathy, refractory to oral prednisone, intravitreal bevacizumab and intravitreal preservative-free triamcinolone. Improvement in vision and resolution of subfoveal fluid was later seen after intravitreal methotrexate therapy.

CONCLUSIONS AND IMPORTANCE:

AEPVM is a rare and poorly understood retinal disorder that may be idiopathic or may manifest in patients with malignancies. The pathogenic process is thought to be an attack directed against the retinal pigment epithelium (RPE) and photoreceptors. Intravitreal methotrexate may provide benefit when treating AEPVM, especially when trials of steroids and anti-VEGF medications have failed.

• Authors: Jie Gao, Ketaki Panse, C Stephen Foster, Stephen D Anesi
• Journal: American journal of ophthalmology case reports (Am J Ophthalmol Case Rep) Vol. 20 Pg. 100930 (Dec 2020) ISSN: 2451-9936 [Electronic] United States
• PMID: 33005818 (Publication Type: Case Reports)
• Copyright: © 2020 The Authors.